Notably, similar to other mutations affecting DNA methylation regulators such as NPM1, IDH2, and CEBPA, DNMT3A mutations have also been shown to upregulate tumor-specific antigens, which in turn can activate antigen-specific clonal T cell responses (68). The gene discussed is DNMT3A; the disease is neoplasm.